Algo version: 0.98b
Hikma Pharmaceuticals PLC is listed at the LSE Exchange
Hikma Pharmaceuticals PLC [HIK.L]
LSE Sector: Industry:Pharmaceuticals, Biotechnology & Life Sciences

Is Hikma Pharmaceuticals PLC stock a buy?

What Is The Conclusion?

Right now our advanced algorithms say:

Do the analyst corps agree?

Interesting Questions and Easy Answers!

Yes, Hikma Pharmaceuticals PLC pays dividends. Last time was Friday 20th of September 2024 where the investors holding the stock on Thursday 15th of August 2024 were paid GBP24.73536 per share. Over the last 38 times between 2006 and 2024, Hikma Pharmaceuticals PLC has paid GBP724.33883 with an average of GBP19.06 per share.

Sorry, we do not have any analyst data for this ticker

We cannot find data for Hikma Pharmaceuticals PLC 10 years ago, but if you had invested on Monday 9th of September 2019 when the price was GBP1 918.00, you would have made a profit of GBP38.00 per share or 1.98%

Yes, the average daily trading liquidity for Hikma Pharmaceuticals PLC is GBP343 705 thousand. You should therefore be able to get in and out of your positions relatively fast.

Hikma Pharmaceuticals PLC has a normal ratio of the business financed by loans. This puts the company at some risk in periods of high inflation where borrowing costs usually go up. With a high cash flow to debt ratio of 0.51, the company's ability to pay off the debt is good. Hikma Pharmaceuticals PLC has a good net profit margin of 6.61% and should have high tolerances against inflation.

We have calculated the inflation risk for Hikma Pharmaceuticals PLC to be low [0.25 of 1]

US inflation for July 2024 was 0.15%. Over the last 12 months, the US inflation is 2.92%. The 10-year treasury yield that indicates the future interest level is currently 3.72 and is down -0.95 over the last 30 days.